Autologous BCMA-targeting CAR T-cells

BCMA-targeted autologous CAR T-cell therapy · Technische Universität Dresden

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous BCMA-targeting CAR T-cells, covering 2025-08-24 to 2025-08-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]

See pricing